argenx NV ADR
$ 844.92
-0.59%
26 Dec - close price
- Market Cap 52,618,445,000 USD
- Current Price $ 844.92
- High / Low $ 854.48 / 842.86
- Stock P/E 36.11
- Book Value 99.66
- EPS 23.40
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.25 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx NV, headquartered in Breda, the Netherlands, is a pioneering clinical-stage biotechnology company dedicated to the development of innovative antibody-based therapies targeting severe autoimmune diseases, hematological disorders, and cancers. Utilizing its proprietary technology platform, the company is advancing a diverse pipeline of therapeutic candidates through various phases of clinical trials, aiming to address significant unmet medical needs and improve patient outcomes. With a strong commitment to scientific innovation and portfolio expansion, argenx presents a compelling investment proposition for institutional investors looking to engage with a dynamic leader in the biopharmaceutical sector.
Analyst Target Price
$1015.52
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-15 | 2025-05-07 | 2025-02-27 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 | 2023-05-07 | 2023-03-02 |
| Reported EPS | 5.18 | 3.2572 | 2.2732 | 0.7125 | 1.39 | 0.45 | -1.04 | -1.68 | -1.25 | -1.69 | -0.71 | -0.7 |
| Estimated EPS | 4.44 | -0.99 | 2.0546 | 1.6979 | 0.03 | -0.98 | -0.86 | -1.7 | -1.54 | -1.73 | -2.26 | -0.7 |
| Surprise | 0.74 | 4.2472 | 0.2186 | -0.9854 | 1.36 | 1.43 | -0.18 | 0.02 | 0.29 | 0.04 | 1.55 | 0 |
| Surprise Percentage | 16.6667% | 429.0101% | 10.6395% | -58.0364% | 4533.3333% | 145.9184% | -20.9302% | 1.1765% | 18.8312% | 2.3121% | 68.5841% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 6.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2025-12-22 08:10:08
Baird has downgraded Argenx (ARGX) to neutral following a recent trial setback for its drug Vyvgart. The downgrade indicates analyst concern regarding the drug's future prospects and potential impact on the company.
2025-12-21 19:09:37
Baird downgraded Argenx SE (ARGX) to Neutral following a late-stage trial setback for its best-selling therapy, Vyvgart. The Dutch biotech's shares traded lower due to concerns over valuation after the negative trial results announced earlier in the week.
2025-12-18 21:09:19
RBC Capital analyst Luca Issi has reaffirmed a Buy rating on Argenx Se (ARGX) with a price target of $925.00. The company recently reported strong quarterly revenues of $947.96 million and a net profit of $245.36 million, a significant improvement from the previous year. This positive outlook is echoed by other analysts, despite a Hold rating from UBS.
2025-12-18 14:10:00
RBC Capital analyst Luca Issi has reaffirmed a Buy rating on Argenx Se (ARGX) with a price target of $925.00. This comes after Argenx Se reported strong quarterly revenue of $947.96 million and a net profit of $245.36 million for the quarter ending June 30. Another firm, Wells Fargo, also issued a Buy rating, while UBS maintained a Hold rating on the stock.
2025-12-17 21:08:59
UBS analyst Xian Deng has maintained a Hold rating on Argenx Se (ARGX), setting a price target of $910.00. This comes despite an overall "Strong Buy" consensus from analysts, with an average price target of $1,008.39 for Argenx Se. The company recently reported strong quarterly revenue and net profit, showing significant growth compared to the previous year.
2025-12-16 21:08:52
argenx SE has announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED). This decision follows a recommendation from an Independent Data Monitoring Committee based on a futility analysis of interim data. While the studies did not meet desired outcomes for efficacy, efgartigimod demonstrated a favorable safety and tolerability profile with no new safety signals identified.
